Cargando…

Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis

Background and Aim: In gastroesophageal reflux disease (GERD), the additive effect of mosapride to a proton pump inhibitor (PPI) is still controversial. This meta-analysis integrated randomized controlled trials (RCTs) in which mosapride combined with a PPI was compared with a PPI alone in GERD trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishizawa, Toshihiro, Mori, Kiyoto, Yoshida, Shuntaro, Ebinuma, Hirotoshi, Toyoshima, Osamu, Suzuki, Hidekazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565487/ https://www.ncbi.nlm.nih.gov/pubmed/32825721 http://dx.doi.org/10.3390/jcm9092705

Ejemplares similares

Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study
por: Lim, Hyun Chul, et al.
Publicado: (2013)

Effects of Encircled Abdominal Compression Device in Colonoscopy: A Meta-Analysis
por: Nishizawa, Toshihiro, et al.
Publicado: (2019)

Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic Review
por: Nishizawa, Toshihiro, et al.
Publicado: (2021)

Long-Term Outcomes of Endoscopic Submucosal Dissection for Colorectal Epithelial Neoplasms: A Systematic Review
por: Nishizawa, Toshihiro, et al.
Publicado: (2022)

Increasing trend of Helicobacter pylori-uninfected gastric cancer without gastric atrophy
por: Nishizawa, Toshihiro, et al.
Publicado: (2022)

Gastric cancer incidence based on endoscopic Kyoto classification of gastritis
por: Toyoshima, Osamu, et al.
Publicado: (2023)

Clinical features of cardiac nodularity-like appearance induced by Helicobacter pylori infection
por: Nishizawa, Toshihiro, et al.
Publicado: (2020)

Risk Factors for Prolonged Hospital Stay after Endoscopy
por: Nishizawa, Toshihiro, et al.
Publicado: (2021)

Small-caliber endoscopes are more fragile than conventional endoscopes
por: Nishizawa, Toshihiro, et al.
Publicado: (2019)

Nodularity-like appearance in the cardia: novel endoscopic findings for Helicobacter pylori infection
por: Toyoshima, Osamu, et al.
Publicado: (2020)

TXI (Texture and Color Enhancement Imaging) for Serrated Colorectal Lesions
por: Nishizawa, Toshihiro, et al.
Publicado: (2021)

Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.
por: Kuipers, E. J., et al.
Publicado: (1999)

Adverse events associated with bidirectional endoscopy with midazolam and pethidine
por: Nishizawa, Toshihiro, et al.
Publicado: (2020)

Efficacy of the four weeks treatment of omeprazole plus mosapride combination therapy compared with that of omeprazole monotherapy in patients with proton pump inhibitor-refractory gastroesophageal reflux disease: a randomized controlled trial
por: Sirinawasatien, Apichet, et al.
Publicado: (2019)

Endoscopic diagnosis for colorectal sessile serrated lesions
por: Nishizawa, Toshihiro, et al.
Publicado: (2021)

Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions
por: Mermelstein, Joseph, et al.
Publicado: (2018)

Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease
por: Shi, Yi-Chao, et al.
Publicado: (2019)

Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy
por: Nishizawa, Toshihiro, et al.
Publicado: (2012)

Comparison of Gastroesophageal Reflux Disease Symptoms and Proton Pump Inhibitor Response Using Gastroesophageal Reflux Disease Impact Scale Questionnaire
por: Jo, So Young, et al.
Publicado: (2013)

Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?
por: Belei, Oana, et al.
Publicado: (2018)

Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease
por: Tariq, Muhammad Ali, et al.
Publicado: (2022)

Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease
por: Shi, Yichao, et al.
Publicado: (2023)

Role of Acid and Weakly Acidic Reflux in Gastroesophageal Reflux Disease Off Proton Pump Inhibitor Therapy
por: Sung, Hea Jung, et al.
Publicado: (2012)

Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection-induced ulcer: a systematic review and meta-analysis
por: Nishizawa, Toshihiro, et al.
Publicado: (2015)

Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease
por: Niikura, Ryota, et al.
Publicado: (2018)

Complete Resolution of Pseudomalignant Erosion in a Reflux Gastroesophageal Polyp with Proton Pump Inhibitor
por: Nakajima, Takahiko, et al.
Publicado: (2015)

Predictive Factors of Response to Proton Pump Inhibitors in Korean Patients With Gastroesophageal Reflux Disease
por: Kim, Sung Eun, et al.
Publicado: (2015)

The simplified Kyoto classification score is consistent with the ABC method of classification as a grading system for endoscopic gastritis
por: Nishizawa, Toshihiro, et al.
Publicado: (2021)

Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy
por: Kawara, Fumiaki, et al.
Publicado: (2017)

Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified?
por: Fossmark, Reidar, et al.
Publicado: (2023)

Real-world clinical data of endoscopy-based cancer detection during the emergency declaration for COVID-19 in Japan
por: Yoshida, Shuntaro, et al.
Publicado: (2020)

Cardiac lymphoid hyperplasia is the same as cardiac nodularity‐like appearance
por: Nishizawa, Toshihiro, et al.
Publicado: (2022)

Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor
por: de Sá, Cláudia Cristina, et al.
Publicado: (2011)

Does Helicobacter pylori eradication or proton pump inhibitor use benefit gastroesophageal reflux disease?
por: Sakin, Yusuf Serdar, et al.
Publicado: (2015)

Putting Out the Fire: The Relationship of Pharmacogenetics and Proton Pump Inhibitors for the Treatment of Gastroesophageal Reflux Disease
por: Zheng, Connor L, et al.
Publicado: (2018)

Can Esophageal Baseline Impedance Predict Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease?
por: Jung, Kyoungwon, et al.
Publicado: (2018)

Is the Diagnostic Trial with Proton Pump Inhibitors Reasonable for School Age Children with Gastroesophageal Reflux Symptoms?
por: Yang, Jaeeun, et al.
Publicado: (2019)

Effect of a Preoperative Proton Pump Inhibitor and Gastroesophageal Reflux Disease on Postoperative Nausea and Vomiting
por: Kwon, Young Suk, et al.
Publicado: (2020)

Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
por: Gotoh, Yasuhiko, et al.
Publicado: (2020)

Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea
por: Park, Susan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ah7h5696geullpnj2pp1eimv9i